Unicycive Q2 net loss narrows to $1.7M; FDA assigns OLC facility inspection

Unicycive Therapeutics, Inc.

2026-Q2 EPS reported -$0.57

Q2 2026 net loss $1.7M ($0.06/sh) vs $6.5M loss ($0.52/sh) in Q2 2025.
Cash, equivalents, and marketable securities $61.4M at June 30, 2026; runway into 2027.
FDA assigned facility inspection to third-party OLC manufacturer; NDA resubmission expected after successful inspection.
June 2026 CRL cited same manufacturing deficiencies as prior CRL; no efficacy or safety concerns.
R&D expense $2.8M (vs $1.8M); G&A $7.4M (vs $5.2M) year-over-year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.